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ABSTRACT
Cisplatin is a cytostatic drug used for treatment of solid organ tumors.
The main adverse effect is organic cation transporter 2 (OCT2)–
mediated nephrotoxicity, observed in 30% of patients. The contribu-
tion of other renal drug transporters is elusive. Here, cisplatin-induced
toxicity was evaluated in human-derived conditionally immortalized
proximal tubule epithelial cells (ciPTEC) expressing renal drug
transporters, including OCT2 and organic anion transporters 1 (OAT1)
or 3 (OAT3). Parent ciPTEC demonstrated OCT2-dependent cisplatin
toxicity (TC50 346 1 mMafter 24-hour exposure), as determined by cell
viability. Overexpression of OAT1 and OAT3 resulted in reduced
sensitivity to cisplatin (TC50 45 6 6 and 64 6 11 mM after 24-hour
exposure, respectively). This effect was independent of OAT-mediated
transport, as the OAT substrates probenecid and diclofenac
did not influence cytotoxicity. Decreased cisplatin sensitivity in
OAT-expressing cells was associated directly with a trend toward
reduced intracellular cisplatin accumulation, explained by reduced
OCT2 gene expression and activity. This was evaluated by Vmax of the
OCT2-model substrate ASP+ (23.5 6 0.1, 13.1 6 0.3, and 21.6 6
0.6 minutes21 in ciPTEC-parent, ciPTEC-OAT1, and ciPTEC-OAT3,
respectively). Although gene expression of cisplatin efflux transporter
multidrug and toxin extrusion 1 (MATE1) was 16.2 6 0.3-fold upregu-
lated in ciPTEC-OAT1 and 6.16 0.7-fold in ciPTEC-OAT3, toxicity was
unaffected by the MATE substrate pyrimethamine, suggesting that
MATE1 does not play a role in the current experimental set-up. In
conclusion, OAT expression results in reduced cisplatin sensitivity in
renal proximal tubule cells, explained by reduced OCT2-mediated
uptakecapacity. In vitrodrug-induced toxicity studies should consider
models that express both OCT and OAT drug transporters.
Introduction
The chemotherapeutic drug cisplatin is commonly used to treat solid
organ tumors located in various tissues, including the head, neck, lung,
testis, ovary, and bladder. Nephrotoxicity is the main adverse effect of
cisplatin, causing acute kidney injury (AKI) in 30% of patients (Hartmann
et al., 1999). AKI is currently the dose-limiting factor in treatment with
cisplatin and is characterized by dysfunction of the proximal tubule.
Cisplatin continues to be prescribed, as less toxic alternatives, including
oxaliplatin, are suggested to have reduced anticancer potential (Wang and
Lippard, 2005; Manohar and Leung, 2018).
Proximal tubule epithelial cells mediate active excretion of xenobi-
otics andmetabolites, and reabsorb low-molecular-weight proteins, such
as b2-microglubulin, and glucose and amino acids filtered by the
glomerulus. To this end, proximal tubule cells express dedicated
membrane-spanning proteins (Nigam et al., 2015). Influx of cisplatin
in proximal tubule cells is critically mediated by organic cation
transporter 2 (OCT2, SLC22A2) (Ciarimboli et al., 2005; Filipski
et al., 2009; Ciarimboli et al., 2010) and ubiquitously expressed copper
transporter 1 (CTR1, SLC31A1) (Pabla et al., 2009), both located in the
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proximal tubule epithelium at the basolateral membrane. Cisplatin is a
substrate for efflux transporters multidrug and toxin extrusion 1 (MATE1,
SLC47A1), and to a lesser extentMATE2-K (SLC47A2), both located at the
apical membrane (Yonezawa et al., 2006; Nakamura et al., 2010). The
combined activity of influx and efflux transporters determines the amount of
cisplatin accumulation, hence correlates to the drug’s nephrotoxicity (Li
et al., 2013). Recent studies indicate that drug-drug interactions and
interindividual genetic differences regarding OCT2 andMATE transporters
may contribute to the nephrotoxic potential of cisplatin, underlining that
their concerted action is essential to maintain active clearance and avoid
proximal tubule accumulation (Sauzay et al., 2016; Chang et al., 2017).
Organic anion transporters 1 (OAT1, SLC22A6) and 3 (OAT3, SLC22A8)
in proximal tubule cells play a main role in clearance of organic anions,
including endogenous uremic toxins and awide range of drugs (Nigam et al.,
2015). Recently, a reduction in renal adverse effects of cisplatin were
demonstrated in an Oat1-knockout mouse model, even though disposition
of this drug is strongly associated with cation transporters (Hu et al., 2017).
The suggested mechanism involves extrarenal metabolism yielding glutathi-
one and cysteine conjugates that act as substrates for OAT transporters.
Moreover, clinical studies demonstrated that cisplatin clearance was
reduced upon cotreatment with OAT-inhibitor probenecid, consistent with
a complete absence of renal adverse effects (Jacobs et al., 1984, 1991). As
cisplatin transport is mediated by neither OAT1 nor OAT3, their role in
cisplatin-induced nephrotoxicity remains to be elucidated.
The present study was designed to investigate the role of OATs
in cisplatin-induced toxicity in conditionally immortalized proximal
tubule epithelial cells (ciPTEC), a human-derived cell line manifesting
proximal tubule characteristics (Wilmer et al., 2010; Nieskens
et al., 2016). In this cell line, we previously demonstrated functional
apical absorption of albumin and phosphate, expression of OCT2,
P-glycoprotein (Pgp, ABCB1), multidrug resistance-associated protein
4 (MRP4, ABCC4), breast cancer resistance protein (BCRP, ABCG2),
and after stable transductions the reintroduction of either OAT1 or
OAT3 (Wilmer et al., 2010; Schophuizen et al., 2013; Jansen et al.,
2014; Nieskens et al., 2016). In addition, ciPTEC express several UDP-
glucuronosyltransferases and consume oxygen, suggesting intact mito-
chondrial energy production (Mutsaers et al., 2013; Schirris et al., 2017).
Therefore, ciPTEC is a relevant proximal-tubule cell model with concerted
action of different transport mechanisms and suitable for in vitro evaluation
of drug-induced toxicity. The results of the present study show CTR1- and
OCT2-dependent cisplatin-mediated toxicity in ciPTEC, which is allevi-
ated in presence of active OAT1 or OAT3. Reduced sensitivity in OAT1-
or OAT3-expressing cells was associated with a trend toward reduced
cisplatin accumulation owing to lower OCT2 uptake capacity. Since
expression of OATs affects toxicity induced by drugs that are typically
imported by OCTs, simultaneous expression of basolateral solute carrier
transport proteins is important for in vitro drug-induced toxicity evaluation.
Materials and Methods
Cell Culture. Conditionally immortalized proximal tubule epithelial cells
(ciPTEC-parent) were developed as described by Wilmer et al. (2010) with
informed consent of the donors in accordance with the approved guidelines of the
Radboud Institutional Review Board. ciPTEC-OAT1 and ciPTEC-OAT3 were
derived from ciPTEC parent cells and demonstrate constitutive expression of
organic anion transporters 1 (OAT1) or 3 (OAT3), respectively, as described by
Nieskens et al. (2016). ciPTEC constitutively expressing enhanced yellow
fluorescent protein (ciPTEC-eYFP) were developed by transduction of eYFP
from the COX8-eYFP vector (Koopman et al., 2006) into the same pLenti4/V5-
DEST vector as used for the OAT constructs, by LR recombinant reaction using
InvitrogenGateway cloning technology (Thermo Fisher Scientific, Carlsbad, CA)
and resulting in expression vector pLenti4/V5-EX-CMV-TetO2-eYFP. Upon
transduction as described for ciPTEC-OAT1 and -OAT3, ciPTEC-eYFP cells
were selected for YFP fluorescence using BD FACSAria Special Order Research
Program (SORP) flow cytometer (BD Biosciences, San Jose, CA). Proliferating
cell culture was maintained up to 90% confluency using T75 culture flasks
(Greiner Bio-One, Kremsmünster, Germany) at 33C and 5% v/v CO2. Cells were
seeded 7 or 8 days prior to the experiment in either T75 culture flasks (Greiner
Bio-One), 12-well plates (Greiner Bio-One), or 96-well plates (Corning Life
Sciences, Corning, New York) with a seeding density of 55,000 cells/cm2 for
ciPTEC-parent, 63,000 cells/cm2 for ciPTEC-OAT1, and 82,000 cells/cm2 for
ciPTEC-OAT3. Cells were subsequently incubated for 24 hours at 33C and 5%
v/v CO2 to stimulate proliferation, followed by 6 or 7 days at 37C and 5% v/v
CO2 to allow differentiation and monolayer formation, referred to as maturation.
Cells were cultured using Dulbecco’s modified eagle medium/HAM’s F12 (Life
Technologies/Thermo Fisher Scientific, Paisley, UK), supplemented with 5 mg/
ml insulin, 5 mg/ml transferrin, 5 mg/ml selenium, 35 ng/ml hydrocortisone,
10 ng/ml epidermal growth factor, 40 pg/ml tri-iodothyronine (MilliporeSigma,
St. Louis, MO), and 10% fetal calf serum (FCS; Greiner Bio-One), and is referred
to as completemedium (CM).Medium inwhich FCSwas omitted, is referred to as
serum-free medium (SFM). The medium was refreshed every 2 to 3 days,
supplemented with 1% penicillin/streptomycin (Invitrogen) only at 33C.
Viability Assay. To evaluate cisplatin-induced toxicity, viability of ciPTEC-
parent, ciPTEC-OAT1, and ciPTEC-OAT3 was evaluated by an MTT assay
(Mosmann, 1983). Briefly, ciPTEC were matured in 96-well plates, washed three
times with SFM, and subsequently exposed to cisplatin (8.7–222 mM;MilliporeSigma)
in SFM for 24 hours. To evaluate the effect of competitive transport inhibitors on
cisplatin-induced toxicity, cisplatin was coexposed with probenecid (100 mM;
MilliporeSigma), diclofenac (50 mM; MilliporeSigma), cimetidine (1.25 mM;
MilliporeSigma), or pyrimethamine (10 and 100 nM; MilliporeSigma). For
probenecid, a pre-exposure during ciPTEC maturation was additionally performed
for 6 days in CM. Following cisplatin exposure, cells were washed three times with
SFM and incubated with 0.5 mg/ml MTT (MilliporeSigma) in SFM for 3 hours at
37C. Formazan crystals formed in viable cells were dissolved in dimethyl
sulfoxide (DMSO; Merck, Darmstadt, Germany) on a microplate shaker (VWR,
Radnor, PA) for 1 hour. Absorption was measured at 560 nm, the background
subtracted at 670 nm, using the BioRad Benchmark Plus (BioRad, Hercules, CA).
All values were normalized to unexposed control. Results were plotted with
GraphPad Prism (version 5.03; GraphPad Software, La Jolla, CA) using nonlinear
regression with four parameters (variable slope) on log-transformed x-values.
Cisplatin Accumulation. To evaluate the effect of OCT2- and MATE-
mediated transport on intracellular cisplatin accumulation, ciPTEC-parent,
ciPTEC-OAT1, and ciPTEC-OAT3 were matured in T75 culture flasks, washed
once in CM, and exposed to cisplatin (250 mM; MilliporeSigma), with and without
OCT2 and MATE substrates cimetidine (1.25 mM; MilliporeSigma) or pyrimeth-
amine (100 nM; MilliporeSigma) in CM for 90 minutes. Cells were washed three
times in Hanks’ buffered salt solution (HBSS) (37C), harvested using Accutase
(Invitrogen), and placed on ice. Cell suspensions were centrifuged at 1500 relative
centrifugal force (rcf) for 5minutes (4C), and cell pellets were resuspended in 200ml
nitric acid (100 mM; Merck). Lysates were obtained by applying three freeze-thaw
cycles of liquid nitrogen and a 37Cwater bath, followed by centrifugation at 10,000
rcf for 10 minutes (4C). Cisplatin content of cell samples was evaluated using an
atomic absorption spectrophotometer, AAnalyst800 (PerkinElmer, Waltham, MA),
equipped with a transversally heated graphite tube atomizer and a platinum hollow
cathode lamp (Photron, Melbourne, Australia), loaded with 20 ml of each sample, as
described in detail before (Durr et al., 2013; Eljack et al., 2014). All values were
corrected for blank (unexposed), normalized to ciPTEC-parent (for uninhibited
control) or uninhibited control of each respective cell line (for competitive inhibitors),
and results were plotted with GraphPad Prism (version 5.03; GraphPad Software).
Gene Expression. To evaluate expression of drug transporter genes involved
in cisplatin influx and efflux, ciPTEC-parent, ciPTEC-OAT1, and ciPTEC-OAT3
were matured in 12-well plates, washed three times, and exposed to SFM for
24 hours, before total RNA was isolated using the RNeasy Mini Kit (QIAGEN,
Hilden, Germany), according to the manufacturer’s instructions. When evaluating
Nrf2 pathway induction, SFMwas supplementedwith 50 nMbardoxolonemethyl
(CDDO-Me; MilliporeSigma), and cDNA was synthesized using M-MLV
Reverse Transcriptase (Promega, Madison, WI), according to the manufacturer’s
instructions. mRNA expression levels of transporters were determined using
gene-specific primer probe sets obtained from Life Technologies: OCT2
(SLC22A2, hs01010723_m1), MATE1 (SLC47A1, hs00217320_m1), MATE2-K
(SLC47A2, hs00945650_m1), MRP2 (ABCC2, hs00166123_m1), NQO1
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(hs01045993_g1), GCLC (hs00155249_m1), GAPDH (hs99999905_m1), and
TaqMan Universal PCRMaster Mix (Applied Biosystems Inc., Foster City, CA).
Real-time quantitative reverse transcription–polymerase chain reactions were
performed using CFX96 Touch Real-Time PCR system (BioRad) according to the
manufacturer’s instructions, and analyzed by CFX Manager software (version 1.6;
BioRad). mRNA levels were calculated using GAPDH as reference gene and
expressed as either2DDCt or fold change (2
2DDCt) compared with ciPTEC-parent.
Results were plotted with GraphPad Prism (version 5.03; GraphPad Software).
ASP Accumulation. To evaluate the accumulation of hOCT2 model substrate
ASP+ (Pietruck and Ullrich, 1995; Cetinkaya et al., 2003), ciPTEC-parent,
ciPTEC-OAT1, and ciPTEC-OAT3were matured in 96-well plates (Schophuizen
et al., 2013). Prior to the experiment, cells were washed three times inHEPES-Tris
buffer, consisting of 132 mM NaCl, 4.2 mM KCl, 1 mM CaCl2, 1 mM MgCl2,
5.5mMglucose, 10mMHepes, buffered to pH 7.4 using Tris (pH 8.8). Cells were
next exposed to ASP+ (4-di-1-ASP+, 0.8–50 mM; Thermo Fisher Scientific,
Waltham, MA) with and without cimetidine (1.25 mM; MilliporeSigma),
pyrimethamine (10 and 100 nM; MilliporeSigma), or probenecid (100 mM;
MilliporeSigma) for 1 hour at 37C. For probenecid, a pre-exposure during
ciPTEC maturation was additionally performed for 6 days in CM to study the
effect of long-term OAT activity inhibition on ASP+-transporting proteins. After
accumulation for 1 hour, the fluorescent signal was measured (excitation 485 nm;
emission 590 nm) using a Victor 3 plate reader (PerkinElmer). Values were
corrected for extracellular signal (empty wells with corresponding ASP+
concentration) and either presented as arbitrary units (for kinetic curves) or
normalized to control (for competitive inhibitors). Results were plotted with
GraphPad Prism (version 5.03; GraphPad Software) using Michaelis-Menten
regression analysis for concentration-dependent transport rate curves.
Glutathione Level. To evaluate total cellular glutathione level, ciPTEC were
matured in six-well plates and glutathione level was evaluated using the
Glutathione Assay Kit (MilliporeSigma), according to the manufacturer’s
instructions. Briefly, cells were harvested using Accutase (Invitrogen), washed
with HBSS, and deproteinized with 5% sulfosalicylic acid (MilliporeSigma).
Lysates were obtained by applying two freeze-thaw cycles of liquid nitrogen and a
37C water bath, followed by a 5-minute incubation on ice and centrifugation at
10,000 rcf for 10minutes (4C). Samplesweremeasured undiluted and absorption
was evaluated at 412 nm every minute for 5 minutes, using Benchmark Plus
(BioRad). All values were corrected for blank, normalized to ciPTEC-parent, and
results plotted with GraphPad Prism (version 5.03; GraphPad Software).
Data Analysis and Statistic. All data analysis and statistics were performed
using GraphPad Prism (version 5.03; GraphPad Software) and presented as mean6
S.E.M. of three independent experiments (n= 3) performed in experimental triplicate,
unless stated otherwise. For calculation of EC50 values, log cisplatin concentration-
versus-viability was plotted after background subtraction. Statistics were performed
by Student’s t test (two-tailed, a = 0.05) or by two-way analysis of variance (two-
tailed, a = 0.05) using the Bonferroni post test (P, 0.05), as indicated in the figures.
Results
The toxic potential of cisplatin was evaluated in parent ciPTEC by
exposure for up to 72 hours, which resulted in a concentration- and time-
dependent loss in cell viability as measured via the MTT assay,
presented in Fig. 1A. To elucidate the role of influx transporter activity
on cisplatin-induced toxicity, ciPTEC-parent was coexposed to cisplatin
in presence of the OCT2 substrate cimetidine or CTR1 substrate CuSO4
for 24 hours. Both substrates significantly attenuated toxicity of
cisplatin, demonstrating their involvement in uptake and related toxicity
of the drug (Fig. 1B). Next cisplatin exposure to ciPTEC expressing
either OAT1 or OAT3 demonstrated reduced sensitivity compared
with ciPTEC-parent, reflected by increased TC50 values, for which the
largest shift was observed for ciPTEC-OAT3 (Fig. 1C; Table 1). The
involvement of OAT-mediated transport in cisplatin-induced toxicity
was investigated further by cisplatin exposure in the presence of OAT
substrates probenecid and diclofenac. These did not affect the cytotox-
icity after 24 hours nor after 7 days of pre-exposure, suggesting that
OAT-mediated influx is not directly involved in reducing cisplatin
sensitivity, nor that OAT transport results in the induction of protective
cellular changes in the long term (Table 1). It should be noted that 7-day
exposure to competitive inhibitor solvent (DMSO, 0.1% v/v) slightly
reduced cisplatin-induced toxicity, which may be explained by in-
activation of the drug by prolonged exposure to DMSO (Table 1) (Hall
et al., 2014). To avoid possible adaptive responses that may have
affected drug sensitivity, cisplatin preconditioning at shorter incuba-
tion times was not performed. Moreover, longer term exposures
Fig. 1. Cisplatin sensitivity in ciPTEC is reduced by OAT1 and OAT3 expression, and is dependent on OCT2- and CTR1-mediated transport. (A) Time- and dose-dependent decrease
in viability of ciPTEC-parent following exposure to cisplatin (8.7–222 mM) for 24, 48, or 72 hours as determined by MTT assay (mean 6 S.E.M., n = 3). (B) Decreased viability of
ciPTEC-parent upon cisplatin exposure could be partially restored by competitive inhibition of OCT2 (1.25 mM cimetidine) or CTR1 (1.25 mM CuSO4) for 24 hours, determined by
MTT assay (mean 6 S.E.M., n = 3, *P , 0.05; **P , 0.01; compared with control by Student’s t test). (C) Reduced sensitivity of ciPTEC-OAT1 and ciPTEC-OAT3 following
exposure to cisplatin (8.7–222 mM) for 24 hours compared with ciPTEC-parent, as determined by MTT assay (mean6 S.E.M., n = 3). Results are normalized to unexposed ciPTEC.
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usually take place in vivo when patients are treated with cis-
platin, making 24- or 48-hour exposures clinically more relevant. To
investigate the intracellular capacity to handle oxidative stress induced
by cisplatin, total glutathione content was analyzed in the three cell lines.
No significant changes were observed in glutathione content between
ciPTEC-parent, ciPTEC-OAT1 (P = 0.44), and ciPTEC-OAT3 (P =
0.56) (Supplemental Fig. 1). As decreased sensitivity to cisplatin might
have resulted from the transduction process used to overexpress OAT1
or OAT3, we evaluated cisplatin sensitivity in ciPTEC-eYFP generated
by the same transduction methodology. No difference in toxicity (P =
0.53) was observed between ciPTEC-eYFP (TC50 39 6 7 mM) and
ciPTEC-parent (TC50 34 6 1 mM, Table 1), supporting our hypothesis
that OAT protein expression is responsible for diminished cisplatin-
sensitivity in OAT1- or OAT3-expressing cells and excluding non-
specific aberrations induced by the transduction methods.
The next step was to determine cisplatin accumulation in the three cell
lines, which showed a reduced trend in ciPTEC-OAT1 (P = 0.29) and
ciPTEC-OAT3 (P = 0.12) compared with ciPTEC-parent after exposure
to excess cisplatin concentrations for 90 minutes (Fig. 2A). Hence,
cisplatin accumulation in the cell lines was directly associated with their
sensitivity to cisplatin as assessed by cell viability. This could have been
the result of decreased OCT2 expression levels or increasedMATE1 and
MATE2-K expression, which facilitate cisplatin influx and efflux,
respectively. ciPTEC expressing OAT3 showed slightly but signifi-
cantly decreased OCT2 (SLC22A2) gene expression of 0.4 6 0.1-fold,
whereas the 0.5 6 0.1-fold reduction in ciPTEC-OAT1was not
significant. On the other hand, MATE1 (SCL47A1) was 16.2 6 0.3-
fold increased in ciPTEC-OAT1 and 6.1 6 0.7-fold in ciPTEC-OAT3
(Fig. 2B; Ct values are shown in Supplemental Table 1). In addition,
MATE2-K gene expression was increased in ciPTEC-OAT1 but
decreased in ciPTEC-OAT3. Although MRP2 (ABCC2) expression
has also been associated with reduced cisplatin sensitivity (Kawabe
et al., 1999), we did not find differential regulation of this drug
transporter between the three cell lines studied (Supplemental Table 2).
To evaluate the functional contribution of influx and efflux transporters
further, cisplatin accumulation was analyzed in the presence of the
TABLE 1
Cisplatin-induced toxicity is independent of OAT-mediated transport in ciPTEC-OAT1 and ciPTEC-OAT3
TC50 values (represented in micromolar) calculated from MTT viability assays following cisplatin (8.7–222 mM) exposure for 24 h are
not affected by 24 h (n = 3) and 7-day (n = 6) competitive inhibition of OAT (probenecid, 100 mM; diclofenac, 50 mM) in ciPTEC-parent,
ciPTEC-OAT1, and ciPTEC-OAT3 (mean TC50 6 S.E.M., *P , 0.05; ***P , 0.001; compared with ciPTEC-parent, no significant
differences were found for treatments by two-way analysis of variance, N.D. is not determined).
Coexposure (24 Hours) Co- and Pre-exposure (7 Days)
– + – +
ciPTEC-parent Probenecid 33 6 3 29 6 4 47 6 4 45 6 3
Diclofenac 34 6 1 34 6 1 N.D. N.D.
ciPTEC-OAT1 Probenecid 53 6 2* 49 6 3 45 6 6 45 6 6
Diclofenac 45 6 6 45 6 4 N.D. N.D.
ciPTEC-OAT3 Probenecid 92 6 8*** 93 6 7*** 80 6 2*** 76 6 6***
Diclofenac 64 6 11* 62 6 13* N.D. N.D.
Fig. 2. Decreased intracellular cisplatin accumulation and OCT2 gene expression in ciPTEC-OAT1 and ciPTEC-OAT3. (A) Whole-cell cisplatin content is decreased in
ciPTEC-OAT1 and ciPTEC-OAT3 compared with ciPTEC-parent, following exposure to cisplatin (250 mM) for 90 minutes. Results are normalized to ciPTEC-parent [mean
6 S.E.M., n = 3, performed with two experimental replicates, no significant differences were found by one-way analysis of variance (ANOVA)]. (B) Gene expression of
OCT2 (SLC22A2) was decreased, but gene expression of MATE1 (SLC47A1) and MATE2-K (SLC47A2) was increased in ciPTEC-OAT1 and ciPTEC-OAT3 compared with
ciPTEC-parent, using GAPDH as reference gene (mean 6 S.E.M., n = 3, performed with one experimental replicate, *P , 0.05; ***P , 0.001; compared with ciPTEC-
parent by one-way ANOVA). (C) Whole-cell cisplatin content is decreased by coexposure to OCT2-substrate cimetidine (1.25 mM) but is not affected by coexposure to
MATE-substrate pyrimethamine (100 nM) during exposure to cisplatin for 90 minutes in ciPTEC-parent, ciPTEC-OAT1, and ciPTEC-OAT3. Results are normalized to
control without substrate (mean 6 S.E.M., n = 3, performed with two experimental replicates, **P , 0.01; compared with control by Student’s t test).
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competitive OCT2 inhibitor cimetidine and resulted in a reduction of
intracellular cisplatin levels that was significant for ciPTEC-OAT1 but
not for ciPTEC-parent (P = 0.32) or -OAT3 (P = 0.33). Pyrimethamine
did not affect cisplatin accumulation at concentrations for which it is a
selective MATE1 substrate (Ito et al., 2010), suggesting a limited role of
MATE-mediated efflux in the current experimental conditions (Fig. 2C).
Competitive MATE inhibition by pyrimethamine did not affect
cisplatin-induced toxicity following coexposure for 24 hours, again
supporting the limited role of MATE in the current conditions (Table 2).
To study the influence of OAT expression onOCT2 protein activity in
more detail, we investigated uptake of ASP+ as specific substrate for the
transporter in all ciPTEC cell lines in presence and absence of OCT2,
MATE, and OAT substrates. Vmax of ASP
+ uptake was significantly
reduced in ciPTEC-OAT1 (13.1 6 0.3 minutes21) and ciPTEC-OAT3
(21.6 6 0.6 minutes21) compared with ciPTEC-parent (23.5 6
0.1 minutes21), suggesting that OCT2-mediated uptake capacity of
ASP+ is reduced in ciPTEC expressing OAT1 or OAT3 (Fig. 3A;
Table 3). As expected, competitive inhibition of OCT2 by cimetidine
reduced ASP+ accumulation (Fig. 3B), whereas the competitive MATE
inhibitor pyrimethamine did not affect ASP+ accumulation, suggesting
that ASP+ is transported by OCT2 and not by MATE, which is in line
with cisplatin accumulation assays (Fig. 3C). Competitive OAT in-
hibition by probenecid did not affect ASP+ accumulation after 24 hours
(Fig. 3D), nor after 7 days (Fig. 3E) of treatment, suggesting that OAT-
mediated uptake did not regulate OCT2 transport capacity.
The Nrf2 pathway is known to attenuate cisplatin-mediated toxicity
by regulation of cisplatin transporters (Atilano-Roque et al., 2016).
Therefore, the involvement of this pathway in the regulation of OCT2
and MATE transporters was evaluated in ciPTEC. Bardoxolone
stimulated the Nrf2 pathway in ciPTEC-parent upon 24-hour exposure
by factors of 6.1 6 0.1 and 4.1 6 0.2, respectively, as assessed by
increasing expression of both target genes, NQO1 and GCLC (Fig. 4A).
This was accompanied by a 1.76 0.2-fold increase inMATE1, an 8.56
0.6-fold increase in MATE2-K, and a 0.36 0.1-fold decrease in OCT2
expression, supporting the nephroprotective effect of Nrf2. A similar
decrease in OCT2 expression was observed for ciPTEC-OAT1 and
ciPTEC-OAT3, as described above. The involvement of Nrf2 in
differential regulation of cisplatin transporters in ciPTEC-OAT1 and
ciPTEC-OAT3 compared with ciPTEC-parent could not be confirmed,
however, as only the Nrf2 target NQO1 was increased 2.76 0.2-fold in
ciPTEC-OAT1, whereas GCLC was neither upregulated in ciPTEC-
OAT1 nor ciPTEC-OAT3 (Fig. 4B). This illustrates that stimulation of
Nrf2 via bardoxolone is distinct from the gene expression pattern
observed in ciPTEC-OAT1 and ciPTEC-OAT3, indicating that the
differences in OCT2 and MATE expression observed are not solely
caused by Nrf2 pathway induction.
Discussion
Cisplatin is a well-described nephrotoxicant, affecting the proximal
tubule in particular. Here, we demonstrate that the human-derived
proximal tubule epithelial cell model, ciPTEC, is sensitive to OCT2- and
CTR1-mediated cisplatin-induced toxicity. Expression of OAT1 and
OAT3 reduced ciPTEC sensitivity to cisplatin, which is independent of
OAT transport activity, and is associated with a trend toward reduced
intracellular cisplatin accumulation, explained by reduced OCT2-
mediated uptake capacity.
The mechanism responsible for reduced cisplatin sensitivity in
ciPTEC-OAT1 and ciPTEC-OAT3 involves reduced OCT2-dependent
influx of the drug. ASP+ is a model substrate for OCT2 and was used to
evaluate OCT2 transport capacity, which was decreased in ciPTEC
expressingOAT.We can only speculate on how this is regulated, but this
could involve the Nrf2 pathway, as Nrf2-null mice developed more
extensive nephrotoxicity after cisplatin treatment compared with wild
types (Aleksunes et al., 2010). Nrf2-mediated signaling reduces
expression of OCT2 in rat cortical tissue and Madin-Darby canine
kidney cells, and increases expression of MATE1 in primary human
proximal tubule cells, reducing renal cisplatin accumulation and toxicity
(Shu et al., 2001; Atilano-Roque et al., 2016; Huang et al., 2017). In
ciPTEC-parent, the involvement of Nrf2 in downregulation of OCT2
and upregulation of MATE1 could be confirmed, supporting previous
in vivo and in vitro studies (Aleksunes et al., 2010; Atilano-Roque et al.,
2016). Remarkably, we found a profound increase of MATE2-K gene
expression, whereas the effect for MATE1 was less pronounced.
Regulation of MATE2-K via Nrf2 when proximal tubule cells were
exposed to flow was recently published (Fukuda et al., 2017). With
respect to cisplatin-induced toxicity, OAT expression affected OCT2
and MATE1/2-K, for which the direct involvement of Nrf2 remains
elusive, as established target genes of this pathway were not consistently
regulated. Therefore, the protective effect on cisplatin toxicity via
bardoxolone-mediated Nrf-2 stimulation was not tested in the current
study focusing on the differential effect of OAT expression. Alterna-
tively, tyrosine kinase inhibitors reduced OCT2 activity and oxaliplatin-
induced acute neuropathy in vivo, suggesting a role for tyrosine
phosphorylation in regulation of OCT2. (Sprowl et al., 2016). It is
important to note that reduction in cisplatin sensitivity and accumulation
was most pronounced for ciPTEC-OAT3, whereas ASP+ accumulation
was reduced mostly in ciPTEC-OAT1. This suggests that additional,
nonelucidated cell-protecting mechanisms in parallel to the Nrf2
pathway or tyrosine kinase activity might play a role in the protection
against cisplatin toxicity.
In addition to drug transport function, OAT1 andOAT3 are associated
with several metabolite pathways, including fatty acid, amino acid,
nucleic acid, glucose, pyruvate, and glutathione metabolism (Ahn et al.,
2011; Wu et al., 2013). As a result, a hypothesis was postulated on the
role of drug transporters in detecting and maintaining levels of
endogenous metabolites, antioxidants, signaling molecules, hormones,
and nutrients (Nigam, 2015; Bush et al., 2017). OAT-mediated transport
is bidirectional and therefore its activity influences the intracellular
concentration of counter-transported compounds, including metabolites
of the citric acid cycle, predominantly a-ketoglutarate (Burckhardt and
Burckhardt, 2003; Sweet et al., 2003; Kaufhold et al., 2011). Reduced or
competitively inhibited OAT function might therefore reduce energy
metabolism, illustrated by reduced active transport of para-amino-
hippuric acid upon inhibition of mitochondrial ATP production (Nagai
et al., 1998). This, in turn, may affect drug-induced toxicity response in
proximal tubules by predisposing to a redox state and supplementing or
depleting the energy pool. Since reactive oxygen species (ROS) are key
players in cisplatin-induced nephrotoxicity, the proximal tubule redox
state and cellular content of the ROS scavenger glutathione are highly
TABLE 2
Cisplatin-induced toxicity is independent of MATE-mediated transport in ciPTEC-
parent, ciPTEC-OAT1, and ciPTEC-OAT3
TC50 values (represented in micromolar) calculated from MTT viability assays following
cisplatin (8.7–222 mM) exposure for 24 h are not affected by competitive MATE inhibition
(pyrimethamine, 10 and 100 nM) in ciPTEC-parent, ciPTEC-OAT1, and ciPTEC-OAT3 (mean
TC50, n = 2).
Control
Pyrimethamine
10 nM 100 nM
ciPTEC-parent 41 45 46
ciPTEC-OAT1 59 57 57
ciPTEC-OAT3 103 111 136
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important for sensitivity to drug-induced toxicity (Wang and Lippard,
2005; Manohar and Leung, 2018). No significant differences in total
glutathione content were observed among the ciPTEC cell lines,
suggesting that redox metabolism is not directly affected by (lack of)
OAT function in ciPTEC. The expression of OAT could have influenced
the intracellular proton gradient, thereby decreasing the membrane
potential, which drives transport by OCTs (Okuda et al., 1999; Budiman
et al., 2000). This might explain the increased Km values for ASP
+
accumulation in ciPTEC-OAT1 and ciPTEC-OAT3 as observed in the
present study. Metabolomic analysis of compounds involved in energy
production, especially of the citric acid cycle, may generate a more
profound understanding of the role of OAT transporters in cellular
homeostasis and drug sensitivity.
The present findings contradict previously reported in vivo studies. Jacobs
et al. (1984, 1991) suggested that cisplatin cotreatment with probenecid
competitively inhibited OAT-mediated transport, thereby reducing the renal
clearance of cisplatin and protecting patients from nephrotoxicity, even at
dose-escalation. In line with this, reduced cisplatin excretion and attenuated
nephrotoxicity were observed in cisplatin-treated Oat1 knockout mice and
probenecid cotreated wild-type mice (Hu et al., 2017). The authors of the
latter study suggested that cisplatin is converted into a highly reactive
mercapturic acid metabolite, which is a substrate for OAT1 and OAT3, in a
way similar to that described for cadmium and mercury (Zalups, 2000a,b;
Cannon et al., 2001). However, the first conversion step involves extrarenal
conjugation of cisplatin to glutathione, generating a water-soluble metabolite
filtered by the glomerulus. Proximal tubule cells are thereforemainly apically
exposed to the conjugated metabolite, suggesting limited involvement of
basolaterally located OAT1 and OAT3. This indicates that current in vitro
Fig. 3. Reduced ASP+ accumulation reflects attenuated OCT2 transport capacity in ciPTEC-OAT1 and ciPTEC-OAT3. (A) ASP+ (0.8–50 mM) accumulation for 60 minutes
is decreased in ciPTEC-OAT1 and ciPTEC-OAT3 compared with ciPTEC-parent, evaluated by intracellular fluorescence intensity after 60 minutes (mean 6 S.E.M., n = 3).
(B–D) ASP+ (3.1 mM) accumulation for 60 minutes in ciPTEC-parent, ciPTEC-OAT1, and ciPTEC-OAT3 is reduced by (B) competitive inhibition of OCT (cimetidine,
1.25 mM) but not affected by competitive inhibition of (C) MATE (pyrimethamine, 10 and 100 nM) or (D) OAT (probenecid, 100 mM), evaluated by intracellular
fluorescence intensity. Results are normalized to unexposed ciPTEC-parent (mean 6 S.E.M., n = 3, *P , 0.05; **P , 0.01; ***P , 0.001; compared with control by
Student’s t test). (E) ASP+ (3.1 mM) accumulation for 60 minutes in ciPTEC-parent, ciPTEC-OAT1, and ciPTEC-OAT3 is not affected by 7-day competitive OAT inhibition
(probenecid, 100 mM), evaluated by intracellular fluorescence intensity. Results are normalized to unexposed ciPTEC-parent (mean 6 S.E.M., n = 2, no significant
differences were found for treatment by Student’s t test).
TABLE 3
ASP+ accumulation is decreased in ciPTEC-OAT1 and ciPTEC-OAT3
Km (represented in micromolar concentration) and Vmax values (represented in min
21)
calculated from Michaelis-Menten fitted ASP+ accumulation assays in ciPTEC-parent, ciPTEC-
OAT1, and ciPTEC-OAT3 (mean 6 S.E.M., n = 3, *P , 0.05; **P , 0.01; ***P , 0.001;
compared with ciPTEC-parent by one-way analysis of variance).
Km Vmax
ciPTEC-parent 2.3 6 0.3 23.5 6 0.1
ciPTEC-OAT1 4.7 6 0.4* 13.1 6 0.3***
ciPTEC-OAT3 6.2 6 0.3*** 21.6 6 0.6**
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models underestimate the complexity of drug-induced renal injury. To
account for the contribution of metabolism, our in vitro model could be
extended to include pre-exposure of cisplatin to cultured hepatocytes or
precision-cut liver slices (Starokozhko et al., 2017). In contrast to studies in
which OAT function contributes to nephrotoxicity, the beneficial effects of
OAT-mediated transport on renal function have also been described.
Ischemia reperfusion resulted in severe kidney injury in rats, which was
accompanied by reduced expression of Oat1 and Oat3. Indomethacin
prevented ischemia-induced downregulation of Oat1 and Oat3, whereas
probenecid abolished indomethacin-mediated attenuation (Schneider et al.,
2015). As cisplatin-induced proximal tubule toxicity can induce a similar
decrease of Oat1 and Oat3 expression (Liu et al., 2012), investigating
indomethacin-mediated regulation of OAT1 and OAT3 might provide an
interesting mechanism that can explain reduced renal adverse effects.
Most in vitro models applied in drug-induced toxicity prediction lack
human- and tissue-relevant expression of transporters and metabolizing
enzymes (Shaw et al., 2002; Chu et al., 2013; Van der Hauwaert et al.,
2014; Wilmer et al., 2016). The proximal tubule model used here
circumvents these issues as it demonstrates a tissue-specific expression
profile in a human-derived stable cell line. To enable drug-induced
toxicity evaluation of compounds that require influx by OAT trans-
porters, OAT1 or OAT3 were reintroduced by lentiviral transfection of
parent ciPTEC, generating ciPTEC-OAT1 and ciPTEC-OAT3
(Nieskens et al., 2016). As this method may have induced genetic
aberrations, a similar transduction process was performed with eYFP to
show that the transfection procedure did not significantly affect cisplatin
sensitivity.
Functional MATE-mediated transport was lacking in our experimen-
tal conditions, illustrated by the inability of pyrimethamine to modulate
ASP+ and cisplatin accumulation, and subsequent cisplatin-induced
toxicity. This may be the result of limited polarization of ciPTEC under
the current culture conditions, although activity of OCT2, OAT1, and
OAT3, which are exclusively expressed at the basolateral membrane
in vivo, was demonstrated. Although pyrimethamine is offered extra-
cellularly, which may compromise inhibition of MATE-mediated
cisplatin extrusion, MATE protein levels were below the limit of
detection with Western blotting in ciPTEC (data not shown). Therefore,
MATE transport function was not studied further in ciPTEC. Additional
experiments using a polarized culture system could be used to enhance
the expression levels and possibly transport activity of MATE1 and
MATE2-K.
ASP+ and cisplatin have been described as MATE1-substrates
in vitro, and MATE1 has been shown to mediate efflux of cisplatin in
rodents in vivo (Yonezawa et al., 2006; Ito et al., 2010; Nakamura et al.,
2010; Wittwer et al., 2013). The driving force for MATE-mediated
transport is a counter-directed gradient of H+ (Tsuda et al., 2007).
Transport of cisplatin was demonstrated upon intracellular acidification,
resulting in a nonphysiologic outward-directed proton gradient and
MATE-mediated influx (Nakamura et al., 2010). All experiments in
ciPTEC were performed at a buffered pH of 7.4, and thus lacked the
driving force for MATE. It is important to consider the limited cationic
charge of cisplatin in buffers that contain a physiologic chloride
concentration, reflecting blood plasma, whereas it is 2-fold positively
charged when exposed to low chloride, reflecting the cytoplasm
(Andersson and Ehrsson, 1995; Jennerwein and Andrews, 1995).
Apparent transport affinities might be different for the neutral or charged
form, possibly affecting accumulation of the drug and further increasing
the mechanistic complexity of cisplatin-induced toxicity. In short, the
in vivo contribution of MATE-mediated efflux to cisplatin-induced
nephrotoxicity in humans remains to be elucidated. Evaluating cisplatin-
induced toxicity in bicompartmental Transwell or three-dimensional
culture models that allow for mimicking of the pH gradient—as is
experienced in the physiologic proximal tubule—may help to elucidate
the involvement of MATE in this process.
In conclusion, we demonstrated that expression of OAT1 or OAT3 in
a human-derived proximal tubule epithelial cell model resulted in
reduced sensitivity to cisplatin. This was independent of OAT transport
function and is most probably explained by a reduced OCT2-mediated
influx capacity. As organic anion transporters influence sensitivity to
drugs that are typically handled by organic cation transporters, reliable
in vitro drug-induced nephrotoxicity evaluation requires simultaneous
expression of basolateral solute carrier transport proteins.
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Supplemental Figure 1: Glutathione content is similar in ciPTEC-parent, ciPTEC-OAT1 and ciPTEC-OAT3. Evaluation of 
whole-cell total glutathione content in ciPTEC-parent, ciPTEC-OAT1 and ciPTEC-OAT3. Results are normalized to ciPTEC-




Supplemental Table 1: Gene expression of OCT2 and MATE1/2-k is differentially regulated between ciPTEC-parent, 
ciPTEC-OAT1 and ciPTEC-OAT3. Ct values of OCT2, MATE1 and MATE2-k derived from RT-qPCR assays following SFM 
exposure for 24 h are within the quantifiable range and are differentially regulated between ciPTEC-parent, ciPTEC-OAT1 and 
ciPTEC-OAT3 (mean Ct±S.E.M., n=3). 
 ciPTEC-parent ciPTEC-OAT1 ciPTEC-OAT3 
    
GAPDH 17.7 ± 0.1 17.9 ± 0.1 17.3 ± 0.1 
OCT2 (SLC22A2) 33.6 ± 0.2 35.0 ± 0.4 34.8 ± 0.2 
MATE1 (SLC47A1) 28.4 ± 0.3 24.6 ± 0.1 25.5 ± 0.1 





Supplemental Table 2: Gene expression of MRP2 is not differentially regulated between ciPTEC-parent, ciPTEC-OAT1 
and ciPTEC-OAT3. Ct values (A.U.) of MRP2 derived from RT-qPCR assays following SFM exposure for 24 h are not 
differentially regulated between ciPTEC-parent, ciPTEC-OAT1 and ciPTEC-OAT3 (mean Ct±S.E.M., n=3). 
 ciPTEC-parent ciPTEC-OAT1 ciPTEC-OAT3 
    
GAPDH 18.0 ± 0.2 18.2 ± 0.5 16.8 ± 0.4 
MRP2 (ABCC2) 33.1 ± 0.6 33.2 ± 0.6 31.6 ± 0.3 
 
